

## Special Issue

# Liver Cancers Molecular Biomarkers Predicting Outcome

### Message from the Guest Editor

We are pleased to invite you to participate in this Special Issue, entitled “Liver Cancers Molecular Biomarkers Predicting Outcome”. The aim of this edition of *Cancers* is to review the most relevant imaging, clinical and molecular biomarkers of liver cancers pertaining to liver-directed therapy. Additionally, we will review relevant targets for immunotherapy in combination with liver-directed therapy. The role of artificial intelligence in facilitating the use of biomarkers in liver-directed therapies will also be explored. Particular attention will be paid to exploring tumor hypoxia and its implications for treatment resistance and systematization. I look forward to receiving your contributions.

### Guest Editor

Dr. Nima Kokabi

Division of Interventional Radiology and Image-Guided Medicine,  
Department of Radiology and Imaging Sciences, Emory University,  
Atlanta, GA 30308, USA

### Deadline for manuscript submissions

closed (10 July 2024)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/136105](https://mdpi.com/si/136105)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)